MedeliX
Start asking

aflibercept

Eylea, Zaltrap · ATC code S01LA05

Key facts
Active substance
aflibercept
ATC code
S01LA05
Authorisation
centrally authorised across the EU (EMA)
Dosage forms
Eylea 40 mg/mL solution for injection in pre-filled syringe. · Eylea 40 mg/mL solution for injection in a vial. · Eylea 114.3 mg/ml solution for injection / Eylea 114.3 mg/ml solution for injection in pre-filled syringe · ZALTRAP 25 mg/ml concentrate for solution for infusion
Marketing authorisation holder
Bayer AG, Sanofi Winthrop Industrie
Information as of
2026-10-27

Key facts

Aflibercept is an inhibitor of new blood vessel formation. As an eye injection (Eylea) it treats retinal diseases; as an infusion (Zaltrap) it is used in metastatic colorectal cancer.

What it is used for

  • Eylea (intravitreal), adults: wet age-related macular degeneration, macular oedema after retinal vein occlusion, diabetic macular oedema, myopic choroidal neovascularisation
  • Eylea 40 mg/mL: retinopathy of prematurity (ROP) in preterm infants
  • Eylea 114.3 mg/ml: wet AMD and diabetic macular oedema
  • Zaltrap (intravenous): metastatic colorectal cancer after an oxaliplatin-containing regimen, with FOLFIRI

Dosing

  • Eylea 40 mg/mL, wet AMD: 2 mg (0.05 mL) monthly for three doses, then every two months; interval may then be individualised
  • Eylea 40 mg/mL, diabetic macular oedema: 2 mg monthly for five doses, then every two months
  • Eylea 40 mg/mL, ROP: single 0.4 mg (0.01 mL) injection per eye
  • Eylea 114.3 mg/ml (AMD, DME): 8 mg (0.07 ml) monthly for 3 doses, then intervals up to every 4 months, later up to 6 months
  • Zaltrap: 4 mg/kg as a 1-hour infusion followed by FOLFIRI, every 2 weeks until progression or unacceptable toxicity
  • Further regimens (e.g. retinal vein occlusion) in the full product information

Contraindications

  • Eylea: hypersensitivity; active or suspected ocular or periocular infection; active severe intraocular inflammation
  • Zaltrap: hypersensitivity to aflibercept; not for ophthalmic/intravitreal use (hyperosmotic)

Important warnings

  • Eylea: endophthalmitis, intraocular inflammation, retinal detachment and cataract after injection; strict aseptic technique and monitoring in the week after injection
  • Eylea pre-filled syringe contains more than the dose: expel excess before injecting
  • Zaltrap: severe, sometimes fatal haemorrhage, GI perforation and fistula formation
  • Zaltrap: hypertension, arterial thromboembolic events, nephrotic syndrome; blood count before each cycle

Side effects

  • Eylea: conjunctival haemorrhage (25%), retinal haemorrhage (11%), visual acuity reduced (11%), eye pain (10%), cataract (8%), intraocular pressure increased (8%)
  • Eylea: serious injection-related eye events in less than 1 in 1,900 injections
  • Zaltrap/FOLFIRI: leucopenia, diarrhoea, neutropenia, proteinuria, stomatitis, fatigue, thrombocytopenia, hypertension

Interactions

  • Eylea: no interaction studies; combination with verteporfin PDT not studied
  • Zaltrap: no pharmacokinetic interaction with FOLFIRI found

Pregnancy and breastfeeding

  • Eylea: contraception during and for at least 3 months (Eylea 114.3 mg/ml: 4 months) after the last injection; use in pregnancy only if benefit outweighs risk
  • Zaltrap: effective contraception during and for 3 months after the last dose; inhibition of angiogenesis may harm pregnancy

Summary of the official product information, written with AI (Claude, Anthropic) on 2026-10-28. Every number was checked automatically against the original text. Not reviewed by a physician – the full official text is authoritative.

Full official text →

Common questions – ask Medelix

For patients

Package leaflet, verbatim

Package leaflet for patients →

Authorisation and brand names by country

Medicines with exactly this active-substance composition, as listed in the national registers – alphabetical and without ranking. Whether a product is currently available is not shown here.

EU – centrally authorised (all member states)

  • Afiveg · biosimilarSTADA Arzneimittel AG · EMEA/H/C/006761
  • Afqlir · biosimilarSandoz GmbH · EMEA/H/C/006150
  • Ahzantive · biosimilarFormycon AG · EMEA/H/C/006607
  • Baiama · biosimilarFormycon AG · EMEA/H/C/005980
  • Eiyzey · biosimilarZaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. · EMEA/H/C/006745
  • Eydenzelt · biosimilarCelltrion Healthcare Hungary Kft. · EMEA/H/C/005899
  • EyleaBayer AG · EMEA/H/C/002392
  • Eyluxvi · biosimilarBiolitec pharma Limited Zweigniederlassung Jena · EMEA/H/C/006282
  • Mynzepli · biosimilarAdvanz Pharma Limited · EMEA/H/C/006438
  • Opuviz · biosimilarSamsung Bioepis NL B.V. · EMEA/H/C/006056
  • Pavblu · biosimilarAmgen Technology (Ireland) UC · EMEA/H/C/006339
  • Vgenfli · biosimilarZaklady FarmaFarmaceutyczne Polpharma S.Aceutyczne Polpharma S.A. · EMEA/H/C/006192
Show all 14 brand names

Source: European Medicines Agency (EMA), product information

Turkey

  • EyleaBAYER TÜRK KİMYA SAN. LTD. ŞTİ. · 3 register entries
  • PavbluAMGEN İLAÇ TİC. LTD. ŞTİ. · 1 register entry
  • YesafiliABDİ İBRAHİM İLAÇ SAN. VE TİC. A.Ş. · 1 register entry
  • ZaltrapSANOFİ SAĞLIK ÜRÜNLERİ LTD. ŞTİ. · 3 register entries

Source: TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, as of 2026-10-16

Brand names in 3 more European countries
Iceland
Afiveg, Afqlir, Ahzantive, Baiama, Eiyzey, Eydenzelt, Eylea, Eyluxvi, Mynzepli, Pavblu, Vgenfli, Yesafili, Zaltrap
Liechtenstein
Afiveg, Afqlir, Ahzantive, Baiama, Eiyzey, Eydenzelt, Eylea, Eyluxvi, Mynzepli, Vgenfli, Yesafili, Zaltrap
Norway
Afiveg, Afqlir, Ahzantive, Baiama, Eiyzey, Eydenzelt, Eylea, Eyluxvi, Mynzepli, Pavblu, Vgenfli, Yesafili, Zaltrap

EMA – Article 57 product data (EU/EEA), 2026-10-28

Medelix receives no money from pharmaceutical companies. Brand names are listed alphabetically and without ranking.

Another question about this substance?

Medelix answers clinical questions from guidelines, studies and product information – every claim with its source.

Sources

  1. European Medicines Agency. Eylea – EPAR, Product Information (OF THE TEXT Detailed information on this medicinal product i). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/eylea-epar-product-information_en.pdf
  2. European Medicines Agency. Zaltrap – EPAR, Product Information (Detailed information on this medicinal product is available ). 2026-10-27. https://www.ema.europa.eu/en/documents/product-information/zaltrap-epar-product-information_en.pdf
  3. TİTCK – Ruhsatlı Beşeri Tıbbi Ürünler Listesi, 2026-10-16. https://www.titck.gov.tr/dinamikmodul/85

Editorial: Medelix editorial team · last updated 2026-10-27 · How these pages are made · Report an error

Source: European Medicines Agency (EMA), product information. Not advertising, not a treatment recommendation. For questions about your own treatment, ask your doctor or pharmacist.